down arrow

Amneal Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03168L1052
USD
11.94
-0.26 (-2.09%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

11.7312.10

52 Week

6.6812.68
Valuation
Technical
Day's Volume

CASH

54.96 k

Shareholding (Mar 2025)

FII

4.31%

Held by 107 FIIs

DII

76.39%

Held by 32 DIIs

Promoter

4.53%

How big is Amneal Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Amneal Pharmaceuticals, Inc. has a market capitalization of $2.45 billion, with net sales of $2.83 billion and a net profit of $32.43 million over the latest four quarters.

As of Jun 18, Amneal Pharmaceuticals, Inc. has a market capitalization of 2,447.77 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 2,830.19 million for the latest four quarters, with a net profit of 32.43 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at -109.27 million and total assets amounting to 3,501.45 million.

Read More

What does Amneal Pharmaceuticals, Inc. do?

22-Jun-2025

Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets generic and branded pharmaceutical products. As of March 2025, it reported net sales of $695 million and a net profit of $25 million, with a market cap of approximately $2.45 billion.

Overview:<BR>Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the development, manufacture, and marketing of bioequivalent pharmaceutical products (generics) and branded products, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 695 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 25 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,447.77 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 58.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -18.42 <BR>Return on Equity: -30.71% <BR>Price to Book: -18.59 <BR><BR>Contact Details:<BR>Address: 400 Crossing Blvd Fl 3, BRIDGEWATER NJ: 08807-2863 <BR>Tel: 1 908 4096700 <BR>Website: https://www.amneal.com/

Read More

Who are in the management team of Amneal Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Amneal Pharmaceuticals, Inc. includes Independent Chairman Paul Meister, Co-CEOs Chirag and Chintu Patel, and several independent directors, including Gautam Patel, Emily Alva, J. Kevin Buchi, Jeffrey George, and John Kiely. This team is responsible for guiding the company's strategic direction.

As of March 2022, the management team of Amneal Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Paul Meister, who serves as the Independent Chairman of the Board.<BR>- Mr. Chirag Patel, who is the President, Co-Chief Executive Officer, and Director.<BR>- Mr. Chintu Patel, who is the Co-Chief Executive Officer, Co-Founder, and Director.<BR>- Mr. Gautam Patel, who is a Director.<BR>- Ms. Emily Alva, who is an Independent Director.<BR>- Mr. J. Kevin Buchi, who is an Independent Director.<BR>- Mr. Jeffrey George, who is an Independent Director.<BR>- Mr. John Kiely, who is an Independent Director. <BR><BR>This team plays a crucial role in guiding the strategic direction of the company.

Read More

Is Amneal Pharmaceuticals, Inc. overvalued or undervalued?

20-Sep-2025

As of March 1, 2024, Amneal Pharmaceuticals, Inc. is considered a risky investment due to its high P/E ratio of 58, negative price-to-book value, and premium EV to EBITDA ratio, despite recent strong stock performance and long-term returns that may not justify its current valuation.

As of 1 March 2024, the valuation grade for Amneal Pharmaceuticals, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, particularly highlighted by its P/E ratio of 58, which significantly exceeds the industry average, and a negative price-to-book value of -17.93. Additionally, the EV to EBITDA ratio stands at 7.91, which, while lower than some peers, still suggests a premium valuation relative to its earnings potential.<BR><BR>In comparison to peers, Amneal's P/E ratio of 48.88 is notably higher than that of NewAmsterdam Pharma Co. NV, which has a P/E of -20.32, and Ardelyx, Inc. with a P/E of -28.16, both indicating a challenging valuation landscape within the sector. Furthermore, despite recent stock performance showing a 21.46% year-to-date return compared to the S&P 500's 12.22%, the long-term returns of 337.27% over three years and 163.56% over five years suggest that the stock has outperformed the benchmark, yet this may not justify its current valuation levels.

Read More

Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Amneal Pharmaceuticals has a bullish technical trend supported by positive weekly indicators, despite some mildly bearish signals on longer timeframes, and has outperformed the S&P 500 in the past month and year-to-date.

As of 5 September 2025, the technical trend for Amneal Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and daily moving averages. However, the monthly MACD and KST are mildly bearish, and the Dow Theory indicates a mildly bearish stance on the weekly timeframe. The OBV shows a mildly bullish trend on both weekly and monthly periods. <BR><BR>In terms of performance, Amneal has outperformed the S&P 500 over the past month (18.33% vs. 2.33%) and year-to-date (21.46% vs. 12.22%), but lags behind over the past year (13.85% vs. 17.14%) and longer periods. Overall, the current technical stance is bullish, with moderate strength driven by positive weekly indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,906 Million (Small Cap)

stock-summary
P/E

58.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-21.41

stock-summary
Return on Equity

-53.04%

stock-summary
Price to Book

-25.92

Revenue and Profits:
Net Sales:
725 Million
(Quarterly Results - Jun 2025)
Net Profit:
36 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
25.03%
0%
25.03%
6 Months
65.6%
0%
65.6%
1 Year
35.53%
0%
35.53%
2 Years
153.5%
0%
153.5%
3 Years
391.36%
0%
391.36%
4 Years
189.1%
0%
189.1%
5 Years
183.61%
0%
183.61%

Amneal Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Amneal Pharmaceuticals, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Amneal Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and daily moving averages. However, the monthly MACD and KST are mildly bearish, and the Dow Theory indicates a mildly bearish stance on the weekly timeframe. The OBV shows a mildly bullish trend on both weekly and monthly periods. In terms of performance, Amneal has outperformed the S&P 500 over the past month (18.33% vs. 2.33%) and year-to-date (21.46% vs. 12.22%), but lags behind over the past year (13.85% vs. 17.14%) and longer periods. Overall, the current technical stance is bullish, with moderate strength driven by positive weekly indicators....

Read More

Is Amneal Pharmaceuticals, Inc. overvalued or undervalued?

As of 1 March 2024, the valuation grade for Amneal Pharmaceuticals, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, particularly highlighted by its P/E ratio of 58, which significantly exceeds the industry average, and a negative price-to-book value of -17.93. Additionally, the EV to EBITDA ratio stands at 7.91, which, while lower than some peers, still suggests a premium valuation relative to its earnings potential. In comparison to peers, Amneal's P/E ratio of 48.88 is notably higher than that of NewAmsterdam Pharma Co. NV, which has a P/E of -20.32, and Ardelyx, Inc. with a P/E of -28.16, both indicating a challenging valuation landscape within the sector. Furthermore, despite recent stock performance showing a 21.46% year-to-date return compared to the S&P 500's 12.22%, the long-term returns of 337.27% o...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
10.41%
EBIT Growth (5y)
30.81%
EBIT to Interest (avg)
1.30
Debt to EBITDA (avg)
5.35
Net Debt to Equity (avg)
-18.42
Sales to Capital Employed (avg)
0.98
Tax Ratio
44.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
53.67%
ROCE (avg)
9.50%
ROE (avg)
12.68%
Valuation key factors
Factor
Value
P/E Ratio
58
Industry P/E
Price to Book Value
-17.93
EV to EBIT
13.13
EV to EBITDA
7.91
EV to Capital Employed
2.09
EV to Sales
1.69
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15.90%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 61 Schemes (14.75%)

Foreign Institutions

Held by 107 Foreign Institutions (4.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.18% vs -4.80% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 44.72% vs 218.84% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "724.50",
          "val2": "695.40",
          "chgp": "4.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "174.10",
          "val2": "157.70",
          "chgp": "10.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "65.10",
          "val2": "56.90",
          "chgp": "14.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.70",
          "val2": "-2.30",
          "chgp": "-17.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "35.60",
          "val2": "24.60",
          "chgp": "44.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "157.40%",
          "val2": "140.30%",
          "chgp": "1.71%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.73% vs 8.20% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -51.75% vs 80.89% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,794.00",
          "val2": "2,393.60",
          "chgp": "16.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "589.50",
          "val2": "492.40",
          "chgp": "19.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "258.60",
          "val2": "210.60",
          "chgp": "22.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-104.00",
          "val2": "-100.60",
          "chgp": "-3.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-73.90",
          "val2": "-48.70",
          "chgp": "-51.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "126.40%",
          "val2": "109.90%",
          "chgp": "1.65%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
724.50
695.40
4.18%
Operating Profit (PBDIT) excl Other Income
174.10
157.70
10.40%
Interest
65.10
56.90
14.41%
Exceptional Items
-2.70
-2.30
-17.39%
Consolidate Net Profit
35.60
24.60
44.72%
Operating Profit Margin (Excl OI)
157.40%
140.30%
1.71%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.18% vs -4.80% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 44.72% vs 218.84% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
2,794.00
2,393.60
16.73%
Operating Profit (PBDIT) excl Other Income
589.50
492.40
19.72%
Interest
258.60
210.60
22.79%
Exceptional Items
-104.00
-100.60
-3.38%
Consolidate Net Profit
-73.90
-48.70
-51.75%
Operating Profit Margin (Excl OI)
126.40%
109.90%
1.65%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 16.73% vs 8.20% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -51.75% vs 80.89% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Amneal Pharmaceuticals, Inc. stock-summary
stock-summary
Amneal Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Generics and Specialty Pharma. The Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Company Coordinates stock-summary
Company Details
400 Crossing Blvd Fl 3 , BRIDGEWATER NJ : 08807-2863
stock-summary
Tel: 1 908 4096700
stock-summary
https://www.amneal.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."